-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 is the 100th anniversary of the founding of the Communist Party of China, the beginning of the "14th Five-Year Plan" period, and the beginning of the new journey of building a modern socialist country in an all-round way
.
Looking back on the arduous history of the Communist Party of China for nearly a hundred years, its centenary birthday, a hundred years of hard work, and a hundred years of vicissitudes, under the call and unity of our party, the Chinese people have worked hard and unswervingly to win national independence and realize national freedom
.
Build a moderately prosperous society in an all-round way and effectively fight the new crown pneumonia epidemic
.
In the 100-year great journey, our party has not changed its original intentions.
The Chinese Communist Party has led the people of all ethnic groups across the country to write epics of magnificent struggles
.
To seek happiness for the Chinese people based on the value concept of the supremacy of the people
.
mCRPC treatment dilemma Prostate cancer is the second most common cancer in men, and its incidence is second only to lung cancer
.
It is estimated that there are more than 1 million newly diagnosed prostate cancer patients each year
.
In addition, most patients have reached a locally advanced stage or have distant metastases at the first diagnosis.
Almost all prostate cancer patients will progress to the stage of metastatic castration-resistant disease (mCRPC)
.
New endocrine therapy and chemotherapy are currently the main treatment methods for mCRPC, but new endocrine sequential therapy and chemotherapy will produce cross-resistance, resulting in an overall survival of less than 3 years
.
Among mCRPC patients, up to 30% of patients have harmful mutations in DNA repair genes, the most common of which is BRCA1/2 gene mutations.
Prostate cancers with BRCA1/2 gene mutations tend to be more malignant and more aggressive.
The higher the proportion of metastatic disease, the worse the survival prognosis of patients, and breakthrough therapies targeting specific gene loci are urgently needed to help mCRPC patients prolong the survival time
.
Olapali: The highly anticipated mCRPC targeted therapy drug In May last year, the FDA quickly approved olapa for the treatment of mCRPC patients with homologous recombination repair (HRR) mutations based on the remarkable efficacy of the PROfound study, only half a year later.
, CDE included AstraZeneca olaparib tablets for prostate cancer indications as a priority review, as a single agent for the treatment of BRCA1/2 mutations (germline and/or somatic cell lines) that appeared after previous treatment with new hormone drugs Adult patients with progressive mCRPC
.
As soon as the news came out, it could be said that one stone stirred up waves
.
The PROfound study is the first large-scale phase III clinical study to guide precise targeted therapy in prostate cancer with molecular typing and achieve positive results.
The disease has progressed after receiving NHA in the past, and it carries homologous recombination repair (HRR) pathway related gene mutations To evaluate the efficacy and safety of olaparib compared with new endocrine therapy in patients with mCRPC
.
The initial results showed that in patients with BRCA 1/2 or ATM mutations, the olaparib group showed excellent statistical significance and clinically significant improvement in terms of the primary endpoint-radiological progression-free survival (rPFS).
Comparing the abiraterone or enzalutamide treatment group, the olaparib group had twice the rPFS prolongation (median rPFS: 7.
4 months vs.
3.
6 months), and the risk of disease progression or death was significantly reduced by 66% (HR=0.
34, 95% CI: 0.
25-0.
47, p<0.
0001)
.
At the ESMO conference last year, the overall survival (OS) results of the PROfound study were shockingly announced.
Olaparib significantly prolonged the OS of patients with BRCA 1/2 or ATM mutations to 19.
1 months.
After correcting the cross-entry patient data, Austria Rapali reduces the risk of death by 58%! It is currently the only PARP inhibitor with overall survival (OS) benefit
.
The results of the PROfound study are powerful, marking that the overall survival of mCRPC patients has once again been greatly extended.
Olapali broke the deadlock and led prostate cancer to officially enter a new era of precision targeted therapy! Olapali is the first PARP inhibitor approved globally and has been included in priority review for many times
.
In February 2018, CDE included olaparib in the priority review and approval procedure for platinum-sensitive recurrent ovarian cancer, and it was approved for marketing in August of the same year; in December of the following year, olaparib was again approved by the Chinese National Drug Administration.
The National Supervision Administration (NMPA) approved the first-line maintenance treatment for patients with BRCA-mutated advanced ovarian cancer.
Up to now, both indications of ovarian cancer have been included in the national medical insurance, allowing a large number of ovarian cancer patients to survive from olaparib maintenance treatment Improve
.
The treatment of mCRPC with olaparib tablets was once again included in the priority review and approval procedure, which greatly shortened the gap with Europe, America and Japan.
All of this is due to the leadership of the party and the support of the government.
The rapid response of the CDE department demonstrates The determination to improve the level of treatment of major diseases
.
The vicissitudes of life, the great changes in China, the long journey of one hundred years, the golden light of one hundred years of journey
.
So far, with great feats and achievements, olaparib is just one of the many anti-tumor drugs that have been quickly approved
.
The party and the government have always taken "for the people's livelihood and health" as their mission, and have not forgotten their original aspirations, leading the people across the country to complete one great health cause after another
.
It is believed that under the guidelines of the "14th Five-Year Plan", the accessibility of medical services will be further enhanced, so that people can use and afford good medicines and new medicines, and benefit more cancer patients
.
Typesetting: Jia Weiwei Editor: Jia Weiwei Review: Qiu Jia For more content, please click: NCF2021 ②∣Academician Han Yaling: Serve patients wholeheartedly, this is not empty talk CACP2021 live report｜Return to the once "battlefield" and reunited in the "hero city" "Physician Daily" 》Public mailbox for submission: yishibao2017@163.
com [Note] Some pictures are from the Internet and WeChat Moments.
If there is any infringement, please contact to delete, thank you! Tel: 010-58302828-6808 Currently 1130000+ doctors have been following to join us
.
Looking back on the arduous history of the Communist Party of China for nearly a hundred years, its centenary birthday, a hundred years of hard work, and a hundred years of vicissitudes, under the call and unity of our party, the Chinese people have worked hard and unswervingly to win national independence and realize national freedom
.
Build a moderately prosperous society in an all-round way and effectively fight the new crown pneumonia epidemic
.
In the 100-year great journey, our party has not changed its original intentions.
The Chinese Communist Party has led the people of all ethnic groups across the country to write epics of magnificent struggles
.
To seek happiness for the Chinese people based on the value concept of the supremacy of the people
.
mCRPC treatment dilemma Prostate cancer is the second most common cancer in men, and its incidence is second only to lung cancer
.
It is estimated that there are more than 1 million newly diagnosed prostate cancer patients each year
.
In addition, most patients have reached a locally advanced stage or have distant metastases at the first diagnosis.
Almost all prostate cancer patients will progress to the stage of metastatic castration-resistant disease (mCRPC)
.
New endocrine therapy and chemotherapy are currently the main treatment methods for mCRPC, but new endocrine sequential therapy and chemotherapy will produce cross-resistance, resulting in an overall survival of less than 3 years
.
Among mCRPC patients, up to 30% of patients have harmful mutations in DNA repair genes, the most common of which is BRCA1/2 gene mutations.
Prostate cancers with BRCA1/2 gene mutations tend to be more malignant and more aggressive.
The higher the proportion of metastatic disease, the worse the survival prognosis of patients, and breakthrough therapies targeting specific gene loci are urgently needed to help mCRPC patients prolong the survival time
.
Olapali: The highly anticipated mCRPC targeted therapy drug In May last year, the FDA quickly approved olapa for the treatment of mCRPC patients with homologous recombination repair (HRR) mutations based on the remarkable efficacy of the PROfound study, only half a year later.
, CDE included AstraZeneca olaparib tablets for prostate cancer indications as a priority review, as a single agent for the treatment of BRCA1/2 mutations (germline and/or somatic cell lines) that appeared after previous treatment with new hormone drugs Adult patients with progressive mCRPC
.
As soon as the news came out, it could be said that one stone stirred up waves
.
The PROfound study is the first large-scale phase III clinical study to guide precise targeted therapy in prostate cancer with molecular typing and achieve positive results.
The disease has progressed after receiving NHA in the past, and it carries homologous recombination repair (HRR) pathway related gene mutations To evaluate the efficacy and safety of olaparib compared with new endocrine therapy in patients with mCRPC
.
The initial results showed that in patients with BRCA 1/2 or ATM mutations, the olaparib group showed excellent statistical significance and clinically significant improvement in terms of the primary endpoint-radiological progression-free survival (rPFS).
Comparing the abiraterone or enzalutamide treatment group, the olaparib group had twice the rPFS prolongation (median rPFS: 7.
4 months vs.
3.
6 months), and the risk of disease progression or death was significantly reduced by 66% (HR=0.
34, 95% CI: 0.
25-0.
47, p<0.
0001)
.
At the ESMO conference last year, the overall survival (OS) results of the PROfound study were shockingly announced.
Olaparib significantly prolonged the OS of patients with BRCA 1/2 or ATM mutations to 19.
1 months.
After correcting the cross-entry patient data, Austria Rapali reduces the risk of death by 58%! It is currently the only PARP inhibitor with overall survival (OS) benefit
.
The results of the PROfound study are powerful, marking that the overall survival of mCRPC patients has once again been greatly extended.
Olapali broke the deadlock and led prostate cancer to officially enter a new era of precision targeted therapy! Olapali is the first PARP inhibitor approved globally and has been included in priority review for many times
.
In February 2018, CDE included olaparib in the priority review and approval procedure for platinum-sensitive recurrent ovarian cancer, and it was approved for marketing in August of the same year; in December of the following year, olaparib was again approved by the Chinese National Drug Administration.
The National Supervision Administration (NMPA) approved the first-line maintenance treatment for patients with BRCA-mutated advanced ovarian cancer.
Up to now, both indications of ovarian cancer have been included in the national medical insurance, allowing a large number of ovarian cancer patients to survive from olaparib maintenance treatment Improve
.
The treatment of mCRPC with olaparib tablets was once again included in the priority review and approval procedure, which greatly shortened the gap with Europe, America and Japan.
All of this is due to the leadership of the party and the support of the government.
The rapid response of the CDE department demonstrates The determination to improve the level of treatment of major diseases
.
The vicissitudes of life, the great changes in China, the long journey of one hundred years, the golden light of one hundred years of journey
.
So far, with great feats and achievements, olaparib is just one of the many anti-tumor drugs that have been quickly approved
.
The party and the government have always taken "for the people's livelihood and health" as their mission, and have not forgotten their original aspirations, leading the people across the country to complete one great health cause after another
.
It is believed that under the guidelines of the "14th Five-Year Plan", the accessibility of medical services will be further enhanced, so that people can use and afford good medicines and new medicines, and benefit more cancer patients
.
Typesetting: Jia Weiwei Editor: Jia Weiwei Review: Qiu Jia For more content, please click: NCF2021 ②∣Academician Han Yaling: Serve patients wholeheartedly, this is not empty talk CACP2021 live report｜Return to the once "battlefield" and reunited in the "hero city" "Physician Daily" 》Public mailbox for submission: yishibao2017@163.
com [Note] Some pictures are from the Internet and WeChat Moments.
If there is any infringement, please contact to delete, thank you! Tel: 010-58302828-6808 Currently 1130000+ doctors have been following to join us
